title: Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
abstract: The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.
authors.affiliation: Department of Neuroradiology, Medical School, University of Tübingen, Berlin, Germany. wilhelm.kueker@orh.nhs.uk
authors.forename: W
authors.initials: W
authors.lastname: Küker
authors.forename: T
authors.initials: T
authors.lastname: Nägele
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: M
authors.initials: M
authors.lastname: Weller
authors.forename: U
authors.initials: U
authors.lastname: Herrlinger
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D003287:Contrast Media; D018450:Disease Progression; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000592:standards*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media